

DAFTAR PUSTAKA

1. Varga MG, Epplen M. Helicobacter pylori -Mediated Carcinogenesis. In: Reference Module in Biomedical Sciences. 3rd ed. New York: Elsevier; 2018. 7–8.
2. Tarigan P. Tukak gaster. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Buku ajar ilmu penyakit dalam. 6th ed. Jakarta: InternaPublishing; 2014. 1783–93.
3. Kavitt RT, Lipowska AM, Anyane A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. *Am J Med.* 2019 Apr;132(4):447–56.
4. Sonnenberg A. Time trends of ulcer mortality in Europe. *Gastroenterology.* 2007 Jun;132(7):2320–7.
5. WHO (2017). World health rankings : peptic ulcer disease. world health organization. [https://www.worldlifeexpectancy.com/indonesia-peptic-ulcer-disease-Diakses September 2019](https://www.worldlifeexpectancy.com/indonesia-peptic-ulcer-disease-Diakses%20September%202019).
6. Rodriguez LA, Hernandez S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. *Am J Epidemiol.* 2004;159(1):23–31.
7. Garrow D, Delege MH. Risk Factors for Gastrointestinal Ulcer Disease in the US Population. *Dig Dis Sci.* 2010;55(1):66–72.
8. Agustian H, Makmun D, Soejono CH. Gambaran endoskopi saluran cerna bagian atas pada pasien dispepsia usia lanjut di Rumah Sakit Cipto Mangunkusumo. *Acta Med Indones.* 2015;2(2):87–9.
9. Sung J, Kuipers J, Serag H. Systematic review: the global incidence and prevalence of peptic ulcer disease. *Aliment Pharmacol Ther.* 2009 May;29(9):938–46.
10. Azhari H. To determine differences in the worldwide incidence of PUD and its complications in different regions at the turn of the 21. 2018;(April):61–2.
11. Furst DE, Ulrich RW, Prakash S. Anti-inflamasi non-steroid, antirematik pemodifikasi penyakit, analgesik non-opioid, & untuk gout. In: Soeharso R, Heriyanto P, Iskandar M, Octavius H, editors. *Farmakologi dasar & klinik.* 12th ed. Jakarta: McGraw-Hill Medical; 2012. 716–22.
12. Kumar V, Abbas AK, Aster JC. Buku ajar patologi robbins. 9th ed. Nasar M, Cornain S, editors. Elsevier. Singapura: Elsevier; 2013. 556–61.
13. Lee SP, Sung I-K, Kim JH, Lee S-Y, Park HS, Shim CS. Risk factors for the presence of symptoms in peptic ulcer disease. *Clin Endosc.* 2017 Nov 30;50(6):578–84.

14. Eisner F, Hermann Di, Bajaeifer K, Glatzle J, Königsrainer A, Küper MA. Gastric ulcer complications after the introduction of proton pump inhibitors into clinical routine: 20-year experience. *Visc Med.* 2017;33(3):221–6.
15. Milosavljevic T, Kostić-Milosavljević M, Jovanović I, Krstić M. Complications of peptic ulcer disease. *Dig Dis.* 2011;29(5):491–3.
16. Thorsen K. Epidemiology of perforated peptic ulcer: Age- and gender-adjusted analysis of incidence and mortality. *World J Gastroenterol.* 2013;19(3):347.
17. Dinas Kesehatan Provinsi Sumatera. Daftar rumah sakit Provinsi Sumatera Barat [internet]. 2017 (diunduh 19 Oktober 2019. tersedia dari : <https://dinkes.sumbarprov.go.id/>).
18. Chaudhry SR, Bhimji SS. Anatomy, abdomen and pelvis, stomach. In: StatPearls. StatPearls Publishing; 2018.
19. Drake RL, Vogl AW, Mitchell A. Gray's basic anatomy. 1st ed. Lewis CC, Lazarus M, Jones BM, Mcbride JM, Hankin MH, editors. Ottawa: Elsevier; 2012. 154.
20. Paulsen F, Waschke J, editors. Sobotta atlas of human anatomy, vol. 2. 15th ed. Munchen: Elsevier; 2011. 78–82.
21. West AB, Mitchell KA. Vascular Disorders of the GI Tract. In: Odze R, Goldblum J, editors. Surgical pathology of the GI tract, liver, biliary tract and pancreas. 2nd ed. Philadelphia: Saunders; 2009. 186–93.
22. Manchanda R, Appukuttan S, Padmakumar M. Electrophysiology of syncytial smooth muscle. *J Exp Neurosci.* 2019 Jan 17;13(1):1–8.
23. Cheng LK, Grady GO, Du P, Egbuji JU, Windsor JA, Pullan AJ. Gastrointestinal System. *Nucl Med.* 2010;2(1):1–11.
24. Sasselli V, Pachnis V, Burns AJ. The enteric nervous system. *Dev Biol.* 2012;366(1):64–9.
25. Parikh A, Thevenin C. Physiology, gastrointestinal hormonal control. In: StatPearls. StatPearls Publishing; 2019.
26. Guyton AC, Hall JE. Guyton and Hall textbook of medical physiology. 12th ed. Gruliow R, Stingelin L, editors. New York: Elsevier; 2012. 208–212 .
27. Hsu M, Lui F. Physiology, Stomach. In: StatPearls. StatPearls Publishing; 2018.
28. Huerta-Franco M-R. Effects of occupational stress on the gastrointestinal tract. *World J Gastrointest Pathophysiol.* 2014;4(4):108–18.

29. Sherwood L. Introduction to human physiology. 8th ed. Alexander S, Glubka A, Crosby L, Oliveira L, editors. California: Brooks-Cole; 2013. 658–62.
30. Sanusi IA. Tukak lambung. In: Rani A, Simadibrata M, Syam AF, editors. Buku ajar Gastroenterologi. 1st ed. Jakarta: InternaPublishing; 2011. 327–40.
31. Aro P, Storskrubb T, Ronkainen J, Bolling-Sternevald E, Engstrand L, Vieth M, et al. Peptic ulcer disease in a general adult population: The kalixanda study: A random population-based study. *Am J Epidemiol*. 2006;163(11):1025–34.
32. Zagari RM, Law GR, Fuccio L, Pozzato P, Forman D, Bazzoli F. Dyspeptic symptoms and endoscopic findings in the community: The loiano-monghidoro study. *Am J Gastroenterol*. 2010;105(3):565–71.
33. Groenen MJM, Kuipers EJ, Hansen BE, Ouwendijk RJT. Incidence of duodenal ulcers and gastric ulcers in a Western population: Back to where it started. *Can J Gastroenterol*. 2009;23(9):604–8.
34. Kurata JH, Haile BM. Epidemiology of peptic ulcer disease. *Clin Gastroenterol*. 1984 May;13(2):289–307.
35. Gurusamy KS, Pallari E. Medical versus surgical treatment for refractory or recurrent peptic ulcer. *Cochrane Libr*. 2016;(3):5–19.
36. AfafShuaib B, Nagah M, Reem-Faleh A, Najah-Salah F, Sara E, Nughaymish A, et al. Profile of peptic ulcer disease and its risk factors in Arar, Northern Saudi Arabia. *Electron Physician*. 2017;9(11):5740–5.
37. Barazandeh F, Yazdanbod A, Pourfarzi F, Sepanlou SG, Derakhshan MH, Malekzadeh R. Epidemiology of peptic ulcer disease: endoscopic results of a systematic investigation in Iran. *Middle East J Dig Dis*. 2012;4(2):90–6.
38. Li Z, Zou D, Ma X, Chen J, Shi X, Gong Y, et al. Epidemiology of peptic ulcer disease: Endoscopic results of the systematic investigation of gastrointestinal disease in China. *Am J Gastroenterol*. 2010;105(12):2570–7.
39. Xie Y, Kang R, Tang D. The Flavone Baicalein and Its Use in Gastrointestinal Disease. In: *Dietary Interventions in Liver Disease*. New York: Elsevier; 2019. 146.
40. Syam AF, Simadibrata M, Wanandi SI, Hernowo BS, Sadikin M, Rani AA. Gastric ulcers induced by systemic hypoxia. *Acta Med Indones*. 2011;43(4):243–8.
41. Chen LS, Lin H, Hwang S, Lee F-Y, Hou M, Lee S. Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. *J Gastroenterol Hepatol*. 1996;11:59–64.

42. Kim M, Kim CS, Bae EH, Ma SK, Kim SW. Risk factors for peptic ulcer disease in patients with end-stage renal disease receiving dialysis. *Kidney Res Clin Pract.* 2019;38(1):81–9.
43. Zelnick EB, Goyal RK. Gastrointestinal manifestation of chronic renal failure. *Semin Nephrol.* 1981;1:124–36.
44. Liang CC, Muo CH, Wang IK, Chang CT, Chou CY, Liu JH, et al. Peptic ulcer disease risk in chronic kidney disease: ten-year incidence, ulcer location, and ulcerogenic effect of medications. *PLoS One.* 2014;9(2):1–7.
45. Bertram TA, Ludlow JW, Basu J, Muthupalani S. Digestive Tract. In: Haschek WM, Rousseaux C, Wallig M, Bolon B, Ochoa R, Mahler BW, editors. *Haschek and Rousseaux's Handbook of Toxicologic Pathology.* 3rd ed. London: Elsevier; 2013. 2345–7.
46. Kumar V, Abul k A, Aster JC. *Buku Ajar Patologi Robbins.* 9th ed. Nasar IM, Cornain S, editors. Singapura: Elsevier; 2015. 557–8.
47. Prabhu V, Shivani A. An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults. *Ann Med Health Sci Res.* 2014;4(1):22.
48. Kirsch JM, Hirsch-Reilly C. Peptic ulcer disease. In: *Acute Care General Surgery.* Germany: Springer International Publishing; 2017. 1449–57.
49. Ramakrishnan K, Salinas R. Peptic ulcer disease. In: *Modern concepts in gastroenterology.* Boston: Springer US; 2007. 1005–11.
50. Brown D, Alvarado JAC. Sepsis (Septic), Peritonitis. In: *StatPearls.* StatPearls Publishing; 2018.
51. Van Rensburg C, Marais M. Management of acute gastric ulcer bleeding. In: Chai J, editor. *South African Gastroenterology Review.* Croatia: InTech; 2012. 9–17.
52. Price S, Wilson LM. *Patofisiologi konsep klinis prosesproses penyakit,* edisi 6. 6th ed. Hartanto H, Susi N, Wulansari P, Asih D, editors. Jakarta: Penerbit Buku Kedokteran; 2006. 423–33.
53. Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and helicobacter pylori infection. *Sci Med.* 2018;115(3):219–24.
54. Dasari ST, Qadrie Z. Peptic Ulcer Desesase: An Overview. *Intern Med.* 2018;12(1):9–26.
55. Mcquaid KR. Obat yang digunakan dalam terapi penyakit saluran cerna. In: Soeharso R, Heriyanto P, Iskandar M, Octavius H, editors. *Farmakologi dasar & klinik.* 12th ed. Jakarta: McGraw-Hill Medical; 2012. 1227–36.

56. Sostres C, Carrera P, Benito R, Roncales P, Arruebo M, Arroyo MT, et al. Peptic ulcer bleeding risk. The role of helicobacter pylori infection in NSAID/low-dose aspirin users. *Am J Gastroenterol.* 2015 May;110(5):684–9.
57. Petrik P, Brašiškienė S, Petrik E. Characteristics and outcomes of gastroduodenal ulcer bleeding: A single-centre experience in Lithuania. *Prz Gastroenterol.* 2017;12(4):277–85.
58. Ng TM, Fock KM, Khor JL, Teo EK, Sim CS, Tan AL, et al. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. *Aliment Pharmacol Ther.* 2000;14(2):203–9.
59. Gkamprela E, Deutsch M, Pectasides D. Iron deficiency anemia in chronic liver disease: Etiopathogenesis, diagnosis and treatment. *Ann Gastroenterol.* 2017;30(4):405–13.
60. Vora RS, Subramanian RM. Hypotension in cirrhosis. *Clin Liver Dis.* 2019;13(6):149–53.
61. Hernández H, Karam J, -Romero F. Factores de riesgo para la recurrencia de úlcera péptica. *Gac Med Mex.* 2001;137(4):303–10.
62. Newton JL. Effect of age-related changes in gastric physiology on tolerability of medications for older people. *Drugs and Aging.* 2005;22(8):655–61.
63. Deding U, Ejlskov L, Grabas MPK, Nielsen BJ, Torp-Pedersen C, Bøggild H. Perceived stress as a risk factor for peptic ulcers: A register-based cohort study. *BMC Gastroenterol.* 2016;16(1):1–12.
64. Barkun A, Leontiadis G. Systematic Review of the Symptom Burden, Quality of Life Impairment and Costs Associated with Peptic Ulcer Disease. *Am J Med.* 2010;123(4):358–66.
65. Curatolo M. Pathophysiology of abdominal pain. *Hogrefe.* 2013;68(8):415–9.
66. Yamane T, Ishii T, Umeda A, Shimao H. Evaluation of six cases of idiopathic astric antral ulcer. *Gastroenterol Res.* 2012;5(3):120–6.
67. Rau W, Hohaus C, Jessen E. A differential approach to form and site of peptic ulcer. *Sci Rep.* 2019;9(1):1–7.
68. Toshihiro N, Suzuki H, Kanai T, Yahagi N. Proton pump inhibitor alone vs proton pump inhibitor plus mucosal protective agents for endoscopic submucosal dissection induced ulcer: a systematic review and meta-analysis. *J Clin Biochem Nutr.* 2015;56(1):85–90.

69. Pittayanon R, Martel M, A B. Efficacy of proton pump inhibitor plus mucoprotective agent for endoscopic submucosal dissection-derived ulcer; a systematic review and meta-analysis of randomized control trial. 2017;2014:297–8.
70. Kavitt RT, Lipowska AM, Anyane A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. *Am J Med.* 2019;132(4):447–56.
71. Syam AF, Setiawati A. Safety and efficacy of lansoprazole injection in upper gastrointestinal bleeding: a postmarketing surveillance conducted in Indonesia. *Acta Med Indones.* 2013;45(2):123–9.
72. Ohmann C, Imhof M, Ruppert C, Janzik U, Vogt C, Frieling T, et al. Time-trends in the epidemiology of peptic ulcer bleeding. *Scand J Gastroenterol.* 2005;40(8):914–20.
73. Arlt GD, Leyh M. Incidence and pathophysiology of peptic ulcer bleeding. *Langenbeck's Arch Surg.* 2001;386(2):75–81.

